We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 176

Causes of action found against Pfizer for a BC class-action certification based on the VIAGRA patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 14 2014

Pfizer had a Canadian patent for VIAGRA that was found to not comply with the disclosure requirement by the Supreme Court in an earlier PM(NOC

Industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Health Canada has opened a Consultation regarding Plain Language Labelling. It is open until September 2, 2014. Health Canada has opened a

FCA refuses to stay injunction order

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Janssen and Abbvie were involved in a patent infringement action. Abbvie was successful in its claim for infringement, and the patent was held to be

The Federal Court finds two generic company's allegations to be unjustified

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Two PM(NOC) decisions relating to the same patent were recently released by the Federal Court. In both cases, the applications were allowed

Patent held invalid for not meeting promise of improved therapeutic profile

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Apotex was successful in the previous NOC Proceeding. It came to market with an esomeprazole product. AstraZeneca sued for patent infringement and

Order of prohibition overturned on appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 16 2014

The issue to be determined by the Court of Appeal related to whether the allegation of lack of utility was justified. The Court of Appeal began by

Final injunction permits existing patients to continue to receive infringing medicine

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 10 2014

This decision relates to the crafting of a final injunction for the sale of STELARA following a finding of infringement. In an earlier trial decision

Clinical studies exempted from public use in allegation of anticipation

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 10 2014

His is an application pursuant to the Patented Medicines (Notice of Compliance) Regulations. The Court began by noting that it had issued an Order of

Court bifurcates determination of Start Date for section 8 action

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 30 2014

This is an action commenced pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations. Pfizer counterclaimed against Apotex

Elevated costs awarded for not dropping a second prohibition proceeding

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 21 2014

Bayer had commenced multiple applications for prohibition against at least two generic companies in respect of its birth control tablets sold under